Geographic Atrophy

Ophthalmology·MeSH: Geographic Atrophy

31 drugs in development·17 companies·11 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
SYFOVRE	Apellis Pharmaceuticals, Inc. (APLS)

Phase 3(9)

Drug	Company
ANX007	Annexon, Inc. (ANNX)
APL-2, Pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
APL-3007, pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
avacincaptad pegol	IVERIC bio, Inc. (ISEE)
Pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
Pegcetacoplan (systemic)	Apellis Pharmaceuticals, Inc. (APLS)
sham	IVERIC bio, Inc. (ISEE)
Systemic pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
Vonaprument	Annexon, Inc. (ANNX)

Phase 2(11)

Drug	Company
ADX-038	ARS Pharmaceuticals, Inc. (SPRY)
APL-3007	Apellis Pharmaceuticals, Inc. (APLS)
BI 1584862	Crinetics Pharmaceuticals, Inc. (CRNX)
fwy003	Novartis AG (NVS)
fwy003	NOVARTIS AG (NVSEF)
JNJ-81201887	Clearside Biomedical, Inc. (CLSDQ)
JNJ-81201887	Crinetics Pharmaceuticals, Inc. (CRNX)
ngm621	NGM BIOPHARMACEUTICALS INC (NGM)
opregen	Lineage Cell Therapeutics, Inc. (LCTX)
sar446597	Sanofi (SNY)
Triamcinolone	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 1(1)

Drug	Company
Pozelimab	REGENERON PHARMACEUTICALS, INC. (REGN)

Preclinical(4)

Drug	Company
4D-175	4D Molecular Therapeutics, Inc. (FDMT)
ic-500	IVERIC bio, Inc. (ISEE)
pas-nomacopan	Akari Therapeutics Plc (AKTX)
szn-113	Surrozen Inc. (SRZN)

Phase 1/Phase 2(3)

Phase 2/Phase 3(1)

Drug	Company
ocu410	Ocugen, Inc. (OCGN)

Phase 4(1)

Drug	Company
Triamcinolone	Clearside Biomedical, Inc. (CLSDQ)

BioSniper tracks 31 drugs in development for Geographic Atrophy across 17 companies.

There are 11 clinical trials targeting Geographic Atrophy tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.